MediWound Ltd. Hits New 52-Week Low at USD 13.53

MediWound Ltd., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 13.53 as of August 13, 2026. This decline marks a significant downturn for the stock, which has experienced a 1-year performance drop of 17.85%, contrasting sharply with the S&P 500's gain of 20.6% during the same period. The company's financial metrics indicate a challenging landscape, with a market capitalization of USD 193 million and a notable negative return on equity of -54.73%. MediWound's price-to-book ratio stands at 4.43, reflecting its valuation relative to its net assets. Additionally, the company has reported a net profit loss of USD 10.14 million, which has grown at a rate of -118.71%. With an operating cash flow of -17.32 million and a debt-equity ratio of -1.20, the financial health of MediWound raises concerns. The stock's performance has been below par both in the short term and over the long term, as it has consistently underperformed against broader market indices.